Should I Be Tested for Cancer?: Maybe Not and Here's Why (2004)
H. Gilbert Welch MD MPH - 30 Q&As - Unbekoming Book Summary
Imagine being told that the smoke detector in your house is so sensitive it can detect a candle burning three blocks away—and that this is somehow supposed to make you safer. This is essentially what has happened with cancer screening over the past several decades. In “Should I Be Tested for Cancer? Maybe Not and Here’s Why,” Dr. H. Gilbert Welch delivers a meticulously researched bombshell that challenges one of medicine’s most sacred assumptions: that finding cancer early saves lives. The truth, as Welch demonstrates through compelling evidence from major studies and real-world data, is far more unsettling. Our increasingly powerful detection technologies—mammograms, PSA tests, CT scans—have indeed become exquisitely sensitive at finding cellular abnormalities we call cancer. But here’s the catch: most of these “cancers” were never going to harm anyone. They’re pseudodisease, cellular irregularities that meet the technical definition of cancer under a microscope but would have sat quietly in the body, never causing symptoms, never threatening life, until something else entirely caused death decades later. Meanwhile, the aggressive cancers that actually kill people tend to grow so fast they sprint through the window between screening appointments, showing up as symptomatic disease regardless of our surveillance efforts.
The scope of this hidden epidemic of overdiagnosis is staggering. Autopsy studies reveal that roughly 40-70% of older men who die from other causes have prostate cancer they never knew about, while careful thyroid examinations find cancer in 36-100% of people, depending on how meticulously pathologists search. A third of women who die from non-cancer causes harbor undiagnosed breast cancer. These aren’t rare anomalies—they represent a vast reservoir of cellular abnormalities that have always existed in human bodies but remained harmless when left undiscovered. When screening programs find these silent cancers in living people, however, everything changes. Suddenly healthy individuals become cancer patients, subjected to surgery, radiation, and chemotherapy for conditions that never threatened them. The neuroblastoma screening disasters in Japan, Quebec, and Germany provide the most damning evidence: these programs doubled the detection of this childhood cancer and achieved impressive “survival” rates, yet the number of children dying from neuroblastoma remained exactly the same. The only achievement was subjecting hundreds of healthy infants to toxic treatments for cancers that would have spontaneously disappeared—some children died from the treatment itself, sacrificed to our compulsion to find and fight every cellular abnormality we can detect.
The medical establishment maintains this illusion through statistical manipulation that would be considered fraudulent in any other field. Five-year survival rates—the metric most often trumpeted as proof that screening works—are fundamentally misleading. These rates automatically improve whenever we diagnose cancer earlier, even if patients die at exactly the same age, because we’re simply starting the survival clock sooner. Welch uses kidney cancer as a perfect illustration: five-year survival improved from 50% to 60% as CT and MRI scans found more small kidney cancers, yet the death rate from kidney cancer remained completely flat. Every person diagnosed with harmless pseudodisease becomes a five-year “survivor,” padding the statistics while gaining nothing from their diagnosis except anxiety and the risks of treatment. Even more troubling is the length bias inherent in screening: slow-growing, relatively harmless cancers linger in the detectable phase for years, making them easy targets for screening tests, while aggressive cancers race through this window in months, becoming symptomatic before the next scheduled test. We’re catching precisely the cancers that don’t need catching while missing the ones that kill. The pathologists themselves operate in a gray zone of uncertainty—studies show they disagree about whether cancer is present in 20-25% of cases, with some pathologists twice as likely as others to diagnose cancer from identical tissue samples. Whether you’re told you have cancer might depend more on which pathologist reviews your slide than on biological reality.
The forces maintaining this system of overdiagnosis run deep through the entire medical-industrial complex. Doctors face asymmetric legal pressure—severe malpractice penalties for missing cancer but none for overdiagnosis—creating powerful incentives to test aggressively. Physicians who own imaging equipment order significantly more scans, generating hundreds of thousands in annual revenue. Hospitals profit enormously from screening programs that create downstream procedures and treatments. Quality metrics reward screening compliance rather than thoughtful patient care, while electronic medical records generate endless reminders for preventive screenings that crowd out time to address patients’ actual concerns. The culture of medicine itself, trained to “do something” rather than watch and wait, views finding disease as success and missing it as failure. Welch reveals how even well-intentioned awareness campaigns transform healthy people into the “worried well,” perpetually anxious about hidden cancers, consuming medical resources in an endless cycle of testing and retesting. The cumulative false positive rate reaches 50% for women undergoing annual mammography for a decade—half will experience a cancer scare requiring additional imaging, biopsies, and sometimes surgery for abnormalities that prove benign. This isn’t healthcare; it’s the mass production of patients, turning a screening test into a gateway drug for medical intervention. The book’s ultimate message is both liberating and deeply uncomfortable: for many people, not looking for cancer might be the healthiest choice they can make. This isn’t nihilism or neglect—it’s recognition that our bodies harbor countless cellular abnormalities that are better left undiscovered, that the aggressive cancers screening purports to catch usually evade our scheduled surveillance anyway, and that transforming healthy people into cancer patients through overdiagnosis might be one of modern medicine’s greatest but least recognized harms.
With thanks to H. Gilbert Welch.
Should I Be Tested for Cancer?: Maybe Not and Here’s Why
Deep Dive Conversation Library (Bonus for Paid Subscribers Only)
This deep dive is based on the book:
Discussion No.144:
Insights and reflections from “Should I Be Tested for Cancer?: Maybe Not and Here’s Why”
Thank you for your support.
Analogy
Imagine you’re the security chief of a large office building, and you’ve heard that occasionally, dangerous individuals try to infiltrate buildings like yours. Concerned about safety, you install increasingly sophisticated detection systems—metal detectors, facial recognition, chemical sensors, behavioral analysis software. The system becomes so sensitive that it flags hundreds of people daily: someone with a fierce expression, another who walked too quickly through the lobby, someone whose backpack contained suspicious liquids (usually coffee), anyone who seemed nervous (often just running late).
Each alert triggers a full investigation—detaining the person, searching their belongings, background checks, sometimes calling in specialists. Most are false alarms, but occasionally you find someone with a pocketknife they forgot about, or expired credentials, or who once had a minor altercation years ago. You treat each case as a serious threat, banning these people from the building, publicizing each “catch” as proof the system works. Meanwhile, the truly dangerous individuals—the ones moving fast with genuine intent to harm—slip through during shift changes or simply break in through windows your system doesn’t monitor. Your building becomes paralyzed by constant security alerts, productive people avoid it because of the hassle, and ironically, you’re so busy processing false alarms that you miss the real threats. This is cancer screening: turning up the detection sensitivity catches more harmless abnormalities while the truly dangerous cancers evade our scheduled observations, and the entire system creates more anxiety and harm than it prevents.
The One-Minute Elevator Explanation
You know how we’re told finding cancer early saves lives? Well, here’s what they don’t tell you: most cancers we find through screening would never have hurt you. It’s like having super-sensitive smoke detectors that go off when you make toast—yes, they detect “smoke,” but was your house really in danger? When we look hard for cancer with mammograms, PSA tests, and CT scans, we find tons of tiny cancers that would have sat there quietly your whole life. But once we find them, we can’t tell which ones are dangerous and which aren’t, so everyone gets surgery, radiation, chemo—the works.
Here’s the kicker: the cancers that actually kill people grow so fast they usually show up between screenings anyway. So we’re catching and treating all these harmless cancers while missing the deadly ones. The statistics they quote you—like five-year survival rates—are completely misleading because of course you survive five years if your “cancer” was never going to hurt you! Want to dive deeper? [Elevator dings] Look up “overdiagnosis in cancer screening,” check out the Cochrane Collaboration’s reviews of screening effectiveness, and research “length-time bias” to understand why screening seems to work when it doesn’t.
12-Point Summary
1. The Fundamental Deception of Early Detection The entire premise of cancer screening rests on a flawed assumption: that cancer inexorably progresses from small to large to deadly. In reality, cancer encompasses a vast spectrum of cellular abnormalities with wildly different behaviors. Some cancers kill quickly regardless of when they’re detected, others grow so slowly that people die of old age first, and many never progress at all or even spontaneously disappear. The harder we look for cancer, the more we find these harmless variants that would have remained buried in our bodies, unknown and unthreatening, if we hadn’t gone searching. Our improved detection technology hasn’t conquered cancer; it’s simply revealed an enormous reservoir of cellular abnormalities that we now treat as disease but which never would have manifested as illness.
2. The Pseudodisease Epidemic Pseudodisease—cancer that meets the pathological definition but will never cause symptoms or death—represents perhaps the greatest unrecognized medical problem of our time. Autopsy studies reveal the shocking scope: roughly 40-70% of older men have prostate cancer, 36-100% of carefully examined thyroids contain cancer, and about a third of women have undiagnosed breast cancer at death. These people died with cancer, not from it. When screening programs find these cancers in living people, they become cancer patients subjected to surgery, radiation, and chemotherapy for conditions that never threatened them. We’ve created a massive epidemic of overdiagnosis, transforming healthy people into patients who can only be harmed by treatment since they were never at risk.
3. The Malignant Mathematics of Survival Statistics Five-year survival rates—the most commonly cited evidence for screening success—represent statistical manipulation that would be criminal in financial markets. These rates inevitably improve with earlier detection through “lead time bias”: finding cancer earlier means people survive longer from diagnosis even if they die at the same age. Additionally, every case of pseudodisease becomes a “success story”—someone who “survived” cancer that never threatened them. Kidney cancer exemplifies this deception perfectly: five-year survival improved from 50% to 60% while death rates remained completely unchanged. The entire statistical framework used to promote screening misleads the public, creating false impressions of medical progress where none exists.
4. The Length Bias That Dooms Screening Screening programs suffer from an insurmountable biological problem: they preferentially detect slow-growing cancers while missing aggressive ones. Fast-growing cancers race through the window between screenings, becoming symptomatic before the next test, while indolent cancers linger for years in the detectable preclinical phase. This length bias means screening fills treatment centers with good-prognosis cancers that didn’t need finding while missing the deadly cancers that kill quickly. The very cancers screening can catch are the ones least needing treatment, while those needing urgent intervention evade periodic testing. It’s a fundamental flaw that no amount of technological improvement can overcome.
5. The Pathologist’s Dilemma Whether you have cancer may depend more on which pathologist examines your biopsy than biological reality. Studies show pathologists disagree about cancer diagnosis in 20-25% of cases, with some pathologists twice as likely as others to diagnose cancer from identical specimens. The cellular differences between inflammation, pre-cancer, and early cancer exist in a gray zone requiring subjective interpretation. Pathologists face enormous pressure not to miss cancer, biasing them toward overdiagnosis. Yet their microscopic observations cannot predict biological behavior—cells that appear threatening may lack the genetic machinery for progression, while innocent-looking cells might harbor dangerous mutations. This subjectivity at the heart of cancer diagnosis undermines the certainty with which treatment decisions are made.
6. The Cascade of Medical Harm Every screening test initiates potential cascades of medical intervention. A suspicious mammogram leads to additional views, ultrasound, MRI, biopsy, and possibly surgery—each with risks. False positives affect 50% of women screened regularly for a decade, creating armies of worried patients undergoing invasive procedures. Some enter endless cycles of surveillance for ambiguous findings, living in permanent uncertainty. The medical system, rather than providing reassurance, generates anxiety and intervention. Physical complications from biopsies, infections from procedures, and even deaths from surgical investigations accumulate. The aggregate harm from investigating false positives and treating pseudodisease likely exceeds benefits from finding real disease.
7. The Economics of Finding Cancer Cancer screening has become a multi-billion-dollar industry with powerful stakeholders invested in finding more cancer regardless of benefit. Hospitals profit from screening programs that generate downstream procedures and treatments. Doctors who own imaging equipment order significantly more scans. Malpractice law severely punishes missing cancer but ignores overdiagnosis, creating legal incentives for excessive testing. Quality metrics reward screening compliance rather than thoughtful patient care. This economic ecosystem depends on maintaining the fiction that more detection equals better health, suppressing acknowledgment of overdiagnosis and screening harms. The financial incentives align perfectly to maximize detection and treatment while minimizing critical evaluation of whether patients actually benefit.
8. The Research That Cannot Be Done Proving screening effectiveness requires studying hundreds of thousands of people for decades—requirements that reveal how marginal any benefits must be. If screening provided substantial benefit, we wouldn’t need enormous studies to detect it. Most screening procedures will never have definitive evidence because the necessary trials are impossibly large, expensive, and long. We operate on educated guesses rather than proof. Even when trials are conducted, they focus on disease-specific mortality rather than overall survival, missing deaths from treatment and other screening consequences. The research infrastructure cannot answer the questions we need answered, leaving screening policy based more on hope and tradition than evidence.
9. The Neuroblastoma Tragedy Neuroblastoma screening programs provide the clearest proof that looking harder for cancer can cause net harm. Japan, Quebec, and Germany screened infants, doubling neuroblastoma detection and achieving excellent survival rates. But population death rates remained unchanged—screening found cancers that would have spontaneously regressed while missing fatal ones. Hundreds of babies underwent toxic treatment for cancers that would have disappeared naturally, suffering surgical complications, secondary cancers from radiation, and treatment deaths. These programs were terminated, but their lesson remains: screening can transform healthy children into cancer patients, subjecting them to harmful treatments for diseases that would have resolved without intervention.
10. The Cultural Dysfunction of Medical Practice Medicine’s culture systematically biases toward overdiagnosis and overtreatment. Medical training rewards finding disease and taking action while rarely acknowledging overdiagnosis or celebrating restraint. “When in doubt, cut it out” remains a medical maxim. Doctors gain satisfaction and income from diagnosis and procedures while thoughtful watching generates neither psychological rewards nor payment. Patients expect action, viewing tests and treatments as care while perceiving watchful waiting as neglect. This cultural dysfunction means medical care systematically errs toward intervention, subjecting patients to unnecessary procedures because doing nothing—even when appropriate—violates deeply embedded medical values that equate action with caring.
11. The Genetic Testing Delusion Genetic testing, promoted as precision medicine’s future, often creates more uncertainty than clarity. Most genetic variants adjust cancer risk slightly—changes too small to clearly dictate action. Having BRCA1 gives women a 50% chance of breast cancer, but half won’t develop it despite the mutation, while 90% of breast cancers occur without known mutations. Genetic information raises unanswerable questions: should young women with moderate risk elevations undergo decades of screening with its false positives and complications, or preventive organ removal with immediate surgical risks? Without evidence about what actually helps, genetic testing creates cohorts of worried well people focused on theoretical future risks while potentially distracted from proven health measures.
12. The Transformation of Healthy People into Patients Cancer screening has medicalized normal life, transforming healthy populations into patients-in-waiting. Awareness campaigns encourage constant bodily vigilance, converting normal variation into potential threats requiring medical evaluation. Millions live as “pre-patients”—women with dense breasts needing extra screening, men with elevated PSA requiring surveillance, people with genetic variants warranting lifetime monitoring. These labels create persistent anxiety about cancers that might never occur. Regular screening means repeated cancer scares, with cumulative false positive rates reaching 50% over a decade. We’ve created a culture where health means the absence of detectable abnormalities rather than the presence of wellbeing, where worried well people consume enormous medical resources that might better serve the actually ill.
The Golden Nugget
The most profound and least known idea in this book is that cancer can spontaneously regress—simply disappear without treatment—and this happens far more often than anyone realizes. Neuroblastoma provides the clearest evidence: screening programs found twice as many cancers as expected, yet when these “extra” cancers were tracked, many vanished on their own. Pathologists have documented cases where confirmed cancers left behind only scar tissue at later examination. This phenomenon isn’t limited to rare cancers—studies suggest that a significant portion of small breast cancers, thyroid cancers, and even some lung cancers may naturally regress if left alone. Our bodies possess powerful mechanisms to eliminate abnormal cells: immune surveillance, apoptosis (cellular suicide programs), and the simple failure of tumors to establish adequate blood supply. The recognition that cancer can resolve without intervention fundamentally challenges the medical imperative to treat every cancer aggressively and immediately. Yet this knowledge remains largely hidden from public discussion because it threatens the entire cancer treatment enterprise and contradicts our cultural narrative that cancer is an inexorable killer requiring immediate medical intervention.
30 Questions and Answers
1. What is the fundamental paradox of early cancer detection that challenges conventional medical wisdom?
The central paradox is that looking harder for cancer and finding it earlier doesn’t necessarily save lives and can actually cause significant harm. While the conventional wisdom holds that early detection is always beneficial—catching cancer when it’s small and before it spreads—the reality proves far more complex. Many cancers detected through screening would never have caused symptoms or death, yet once found, they trigger aggressive treatment with all its attendant risks, costs, and anxieties.
This paradox exists because cancer isn’t a single disease progressing inevitably from small to large to deadly. Instead, cancer represents a spectrum of cellular abnormalities with vastly different behaviors. Some cancers grow rapidly and kill quickly regardless of when they’re found, others grow so slowly that people die of other causes first, and some don’t progress at all or even spontaneously regress. The harder we look with increasingly sensitive tests, the more we find these harmless cancers that would have remained hidden in previous eras, creating a situation where medical intervention makes healthy people sick rather than sick people well.
2. What is pseudodisease and why does it represent such a significant problem in cancer screening?
Pseudodisease refers to cancers that meet the cellular definition of cancer under the microscope but will never cause symptoms or death. These include nonprogressive cancers that stop growing or shrink on their own, and very slow-growing cancers where patients die of other causes long before the cancer becomes problematic. These cellular abnormalities look like cancer, are diagnosed as cancer, and get treated as cancer, but they were never destined to harm the patient.
The problem is that doctors cannot reliably distinguish pseudodisease from real threats by looking at cells under a microscope. Once diagnosed, these patients face the full emotional burden of a cancer diagnosis and undergo surgery, radiation, or chemotherapy—treatments that carry real risks including death—without any possibility of benefit since they were never in danger. Studies suggest that a substantial portion of cancers found through screening, particularly prostate and breast cancers, represent pseudodisease. The more aggressively we screen, the more pseudodisease we find, creating an epidemic of overdiagnosis and overtreatment.
3. How does the “window of opportunity” for cancer detection work, and why do screening tests often miss the most dangerous cancers?
The window of opportunity is the preclinical phase when a cancer exists but hasn’t yet caused symptoms—the only time screening can potentially detect it. This window varies dramatically between cancers. Fast-growing aggressive cancers have very short windows, perhaps just months, while slow-growing cancers may have windows spanning decades. The length of this window determines both the likelihood of detection and the potential benefit of finding the cancer.
Paradoxically, screening tests preferentially detect slow-growing cancers with long windows of opportunity while missing the aggressive cancers we most need to catch. Fast-growing cancers sprint through their brief window between screening intervals, becoming symptomatic before the next scheduled test. Meanwhile, slow-growing cancers linger in their extended window, making them easy targets for detection. This “length bias” means screening fills treatment centers with people who have the best prognoses regardless of intervention, while those with aggressive cancers appear with symptoms between screenings, creating the illusion that screened cancers have better outcomes simply because we’re comparing fundamentally different diseases.
4. Why is the five-year survival rate considered the world’s most misleading statistic in cancer care?
Five-year survival rates measure the percentage of people alive five years after cancer diagnosis, and they inevitably improve with earlier detection even when no lives are saved. If screening detects cancer two years earlier but doesn’t change when someone dies, they still survive longer from the time of diagnosis simply because we started counting sooner. This “lead time bias” makes screening appear effective when it merely provides advance notice of death without postponing it.
Additionally, five-year survival rates are inflated by finding pseudodisease—cancers that were never going to cause death. Every person diagnosed with harmless cancer through screening becomes a five-year survivor, artificially boosting survival statistics. Kidney cancer exemplifies this distortion: five-year survival improved from 50% to 60% as imaging technology found more small kidney cancers, yet the death rate from kidney cancer remained completely unchanged. The statistic suggests dramatic progress where none exists, making it a powerful but deceptive marketing tool for screening programs.
5. What is lead time bias and how does it create the illusion that screening saves lives when it may not?
Lead time bias occurs because survival is measured from the moment of diagnosis rather than the actual beginning of the disease. When screening detects cancer earlier, it automatically extends the measured survival time even if the person dies at exactly the same age they would have without screening. A cancer destined to kill at age 70 appears as a three-year survival if found at age 67 through symptoms, but as a seven-year survival if detected at age 63 through screening, creating false evidence of benefit.
This bias profoundly distorts our understanding of screening effectiveness. Programs claiming dramatic improvements in survival rates may simply be diagnosing cancers earlier without changing outcomes. The bias is further compounded because earlier detection also means more years of knowing you have cancer, more years of treatment side effects, and more years of anxiety—none of which are captured in survival statistics. Only mortality rates, which measure deaths in entire populations regardless of diagnosis timing, can reveal whether screening actually saves lives rather than merely providing earlier bad news.
6. How does DCIS (ductal carcinoma in situ) illustrate the problem of overdiagnosis in breast cancer?
DCIS represents tiny breast cancers confined to milk ducts that were virtually unknown before mammography. Since the 1980s, DCIS diagnoses have skyrocketed from fewer than 5,000 to over 60,000 cases annually, yet invasive breast cancer rates haven’t declined correspondingly. If DCIS routinely progressed to invasive cancer, finding and treating it should reduce invasive cancer incidence, but this hasn’t happened. Studies show that even when DCIS is missed at biopsy, most women never develop invasive breast cancer, suggesting the majority represents pseudodisease.
Despite this evidence, DCIS is treated as aggressively as invasive cancer with surgery, radiation, and medication. Nearly half a million women have been diagnosed and treated for DCIS since widespread mammography began—women who underwent mastectomies or lumpectomies with radiation for a condition that likely would never have harmed them. The DCIS epidemic demonstrates how technological advances in detection capability, rather than genuine increases in disease, can create new categories of patients who cannot benefit from treatment because they were never truly at risk.
7. Why do pathologists disagree so frequently about cancer diagnoses, and what does this mean for patients?
Pathologists examining the same tissue samples disagree about the presence of cancer in roughly 20-25% of cases, particularly for borderline abnormalities. Studies where multiple pathologists review identical slides reveal substantial variation in diagnosis, with some pathologists twice as likely as others to diagnose cancer. This disagreement is highest for small, early cancers—precisely what screening detects. The cellular differences between inflammation, pre-cancer, and early cancer can be extremely subtle, requiring subjective interpretation of cell size, shape, organization, and architecture.
For patients, this means whether you’re told you have cancer may depend more on which pathologist examines your biopsy than on biological reality. The pathologist’s threshold for calling something cancer, their experience, even the pressure they feel to avoid missing cancer all influence diagnosis. This subjectivity is particularly troubling because cancer diagnosis triggers aggressive treatment. Patients face life-altering medical interventions based on interpretations that might differ if another equally qualified pathologist had reviewed the slides, highlighting how the apparent certainty of cancer diagnosis masks considerable uncertainty.
8. What evidence from autopsy studies reveals about how common undiagnosed cancers really are?
Autopsy studies consistently find substantial reservoirs of undiagnosed cancer in people who died from other causes. Roughly one-third of women who die from non-cancer causes have undiagnosed breast cancer, while 40-70% of older men have prostate cancer at autopsy. Thyroid cancer appears in 36-100% of autopsies depending on how carefully pathologists look, and lung cancer is found in about 1% of non-smokers who died from other causes. These cancers existed but never caused symptoms during life.
These findings revolutionize our understanding of cancer prevalence and behavior. If we could scan living populations with the thoroughness of autopsy examination, we’d find enormous amounts of cancer that never needs treatment. The reservoir of hidden cancer means that any improvement in detection technology—better imaging, more sensitive tests, more frequent screening—will inevitably find more of these harmless cancers. The autopsy data proves that dying with cancer is far more common than dying from cancer, and that much of what we call cancer represents a normal part of aging rather than a disease requiring intervention.
9. How do false positive test results create cascading cycles of testing and anxiety?
False positive results occur in 5-10% of individual screening tests, but the cumulative risk over multiple screenings is far higher. A woman undergoing annual mammography for a decade faces a 50% chance of at least one false positive. Each false positive triggers a cascade: repeat imaging, ultrasounds, MRIs, biopsies, and sometimes surgical procedures. Some patients enter endless cycles of ambiguous results requiring perpetual monitoring, living in permanent uncertainty about whether they have cancer.
The psychological toll extends beyond temporary anxiety. Studies show that women experiencing false positive mammograms report increased worry about breast cancer months or even years later. Some patients become hypervigilant, interpreting normal bodily sensations as potential cancer symptoms. Others develop such anxiety that they pursue aggressive interventions like preventive mastectomies. The medical system, rather than providing reassurance, creates a population of worried well people who might have been better off never being tested, transforming healthy individuals into perpetual patients.
10. What happened with neuroblastoma screening that proved looking harder for cancer can actually cause more harm than good?
Japan pioneered neuroblastoma screening in infants during the 1980s, testing six-month-olds’ urine for cancer markers. The program dramatically increased neuroblastoma detection, finding nearly twice as many cases. Treatment appeared highly successful with excellent survival rates. However, when researchers examined population-wide death rates from neuroblastoma, they found no reduction whatsoever. The screening was finding extra cancers that would have spontaneously regressed—a known phenomenon in neuroblastoma—without preventing any deaths.
The implications were devastating: hundreds of infants underwent unnecessary surgery, chemotherapy, and radiation for cancers that would have disappeared naturally. Some suffered serious treatment complications including secondary cancers, while others died from treatment itself. When similar screening programs in Quebec and Germany produced identical results—increased diagnosis with no mortality benefit—the evidence became undeniable. These programs were terminated, providing the clearest demonstration that cancer screening can cause net harm, subjecting healthy children to toxic treatments for a disease that would have resolved without intervention.
11. Why does finding more thyroid cancer through improved imaging not reduce thyroid cancer deaths?
Thyroid cancer detection has increased dramatically with ultrasound and CT scanning, yet death rates remain flat at about 0.5 per 100,000 people. Finland’s experience proves this disconnection: different regions varied 3-fold in thyroid cancer detection rates based on how aggressively pathologists searched for cancer, yet all regions had identical mortality. Autopsy studies reveal why—virtually everyone has thyroid cancers if you look carefully enough, with prevalence ranging from 36% to 100% depending on sectioning thoroughness.
This demonstrates that most thyroid cancers represent pseudodisease that never threatens life. The small cancers found through improved imaging were always present in the population but remained harmless when undetected. Now these people undergo thyroidectomy with its risks of surgical complications, lifelong hormone replacement, and potential damage to vocal cords and parathyroid glands. The stable death rate despite dramatically increased detection and treatment proves we’re not preventing deaths but rather converting healthy people into cancer patients, creating an epidemic of diagnosis without addressing real disease.
12. How do financial incentives and malpractice fears drive unnecessary cancer testing?
Doctors who own imaging equipment order significantly more scans than those who don’t, with some earning hundreds of thousands annually from scanning revenue alone. Hospitals profit enormously from cancer treatment, creating powerful incentives to find more cancer through aggressive screening programs. Mammography centers in competitive markets advertise aggressively and push supplemental screening technologies. The medical-industrial complex has transformed cancer screening into a multi-billion dollar industry where finding more cancer, regardless of benefit, generates revenue.
Malpractice fears compound these incentives. Doctors face lawsuits for missing cancer but almost never for overdiagnosis or unnecessary treatment. The legal system’s asymmetric punishment—severe penalties for underdiagnosis, none for overdiagnosis—drives defensive medicine. After malpractice suits, doctors order significantly more tests, refer more patients to specialists, and lower their thresholds for recommending biopsies. This legal climate makes it professionally safer to test everyone repeatedly than to thoughtfully consider whether testing might cause more harm than good, creating a one-way ratchet toward ever more aggressive screening.
13. What is the difference between absolute risk and relative risk, and why does this distinction matter for screening decisions?
Absolute risk represents your actual chance of experiencing an outcome, while relative risk compares two absolute risks. If screening reduces colon cancer death risk from 3 per 1,000 to 2 per 1,000, the absolute risk reduction is 1 per 1,000—meaning 999 of 1,000 people receive no benefit. However, this same data yields a relative risk reduction of 33% (one-third fewer deaths), which sounds dramatically more impressive despite describing the identical small benefit.
This distinction critically affects screening decisions because medical marketing emphasizes relative risk while hiding absolute numbers. A “50% reduction in death” might mean dropping from 2 per 10,000 to 1 per 10,000—helping one person while 9,999 undergo screening unnecessarily. Understanding absolute risk reveals that most people, even in high-risk groups, won’t benefit from screening. The manipulation of risk presentation—using whichever metric sounds most compelling—represents a form of statistical deception that inflates perceived benefits while minimizing apparent harms, preventing truly informed decision-making.
14. Why do randomized controlled trials of cancer screening require hundreds of thousands of participants?
Cancer screening trials need enormous populations because they’re looking for tiny effects in rare events. Even common cancers kill relatively few people in screened age groups over study periods. Detecting a 25% reduction in deaths from a cancer that kills 30 per 100,000 people means identifying a difference of 7.5 deaths per 100,000—requiring hundreds of thousands of participants to distinguish this small signal from random statistical noise. The rarer the cancer or smaller the benefit, the more participants needed.
These massive requirements reveal an uncomfortable truth: if screening benefits were substantial, we wouldn’t need such enormous studies to detect them. The fact that proving screening works requires studying cities’ worth of people suggests the benefits are marginal. Moreover, these trials take decades and cost hundreds of millions of dollars, making it impossible to test every screening variation. We’ll never have definitive trials for different screening intervals, ages to start and stop, or technology improvements, meaning most screening decisions rest on educated guesses rather than solid evidence.
15. What were the major controversies surrounding the mammography trials, and what did they reveal about screening effectiveness?
The mammography trials generated fierce controversy with different studies reaching opposite conclusions. The Canadian trials found no benefit for women in their 40s and no advantage of mammography over careful physical examination for women in their 50s, while Swedish studies showed mortality reductions. Critics attacked the negative studies’ methodology, alleging improper randomization and poor mammogram quality, while defenders questioned whether positive studies properly attributed deaths and controlled for other interventions.
The Cochrane Collaboration’s analysis revealed that studies showing benefit had serious methodological flaws while well-conducted studies showed minimal or no benefit. The controversy exposed how researcher bias, financial interests, and institutional investment in screening programs influence both study design and interpretation. Most tellingly, the debates revealed that after 40 years and nearly 500,000 women in trials, we still can’t definitively say whether mammography saves lives, suggesting that any benefit is certainly smaller than originally hoped and possibly nonexistent.
16. How does cancer incidence increase dramatically with more testing while mortality rates remain unchanged?
Kidney cancer incidence doubled as CT and MRI scans became routine, thyroid cancer tripled with ultrasound adoption, and melanoma incidence soared with increased biopsies, yet death rates for these cancers remained flat. This pattern—rising incidence with stable mortality—proves we’re not catching dangerous cancers early but rather discovering a vast reservoir of nonprogressive disease. Prostate cancer showed the most dramatic example: incidence skyrocketed with PSA testing in the 1990s then plummeted when recommendations changed, while mortality remained unaffected throughout.
This disconnection between incidence and mortality exposes the failure of the early detection paradigm. If screening caught dangerous cancers early enough to cure them, increased detection should reduce deaths. Instead, we see massive overdiagnosis—finding cancers that would never have caused harm. The stable mortality amid dramatically increased detection and treatment indicates we’re subjecting thousands to unnecessary surgery, radiation, and chemotherapy without preventing deaths, creating epidemics of diagnosis that represent healthcare system failures rather than disease burdens.
17. What role does the prostate gland’s natural changes with aging play in PSA testing controversies?
The prostate naturally enlarges with age, and PSA levels rise correspondingly, making it impossible to establish a meaningful “normal” threshold. Most PSA elevations result from benign prostatic enlargement, not cancer, creating massive false positive rates that increase with age precisely when true cancer risk also rises. The test cannot distinguish between benign growth, inflammation, and cancer, leading to countless unnecessary biopsies. Even worse, the cancers PSA testing finds are predominantly slow-growing tumors that would never cause symptoms during a man’s lifetime.
Autopsy studies show 70% of 80-year-old men have prostate cancer, yet only about 3% of men die from it, meaning most prostate cancer is pseudodisease. PSA testing transforms this vast reservoir of harmless cancer into diagnosed disease requiring treatment. The test’s inability to differentiate threats from normal aging means millions of men undergo biopsies, surgery, and radiation for conditions that would never have harmed them, experiencing impotence, incontinence, and other complications from treating their aging prostates as though they harbored dangerous disease.
18. How can genetic testing for cancer risk create more uncertainty rather than clarity?
Genetic testing rarely provides definitive answers about cancer risk. Having the BRCA1 mutation gives women a 50% chance of developing breast cancer by age 70—meaningful information, but half won’t develop cancer despite the mutation. Meanwhile, 90% of breast cancers occur in women without known genetic mutations. Most genetic variants modify risk slightly—raising it from 2% to 6% or lowering it from 10% to 5%—changes too small to clearly dictate different actions. People receive probability adjustments rather than certainty.
Furthermore, genetic testing raises unanswerable questions about intervention. Should a 20-year-old with moderately elevated ovarian cancer risk undergo decades of screening with its false positives and complications, or preventive ovary removal with its immediate surgical risks and hormonal consequences? Without evidence about which approach actually helps, genetic information becomes a burden rather than a tool. Testing creates cohorts of worried well people focused on theoretical future risks while potentially distracted from proven health measures like exercise, not smoking, and addressing current medical issues.
19. Why might “watchful waiting” be a better strategy than immediate treatment for many early cancers?
Watchful waiting recognizes that many cancers never progress or progress so slowly that other diseases become more relevant. By monitoring cancers over time rather than immediately treating them, doctors can identify the minority that show aggressive behavior requiring intervention while sparing others unnecessary treatment. This approach acknowledges our inability to predict cancer behavior from static cellular appearance and instead uses dynamic observation to guide decisions.
The strategy works particularly well for prostate cancer, where studies show similar survival between immediate treatment and watchful waiting, but vastly different quality of life. Men who wait avoid or delay impotence, incontinence, and other treatment complications. Similar approaches are being studied for small kidney cancers, DCIS, and thyroid cancers. Watchful waiting requires accepting uncertainty and resisting the powerful psychological urge to “do something,” but it prevents the certain harms of treatment for those with uncertain disease while preserving the option to treat if progression occurs.
20. How does the culture of medicine promote a “do something” mentality that may harm patients?
Medical training rewards finding disease and taking action while rarely acknowledging the possibility of overdiagnosis or celebrating restraint. Doctors fear missing diagnoses far more than making unnecessary ones, reinforced by a malpractice system that punishes errors of omission but ignores errors of commission. The medical maxim “when in doubt, cut it out” exemplifies this action bias. Physicians gain satisfaction from making diagnoses and performing procedures, activities that feel productive and are well-compensated, while thoughtful observation generates neither psychological rewards nor income.
Patients contribute to this dynamic by expecting action from medical encounters. Ordering tests and prescribing treatments satisfies patients’ desire for “something to be done” while counseling patience or explaining why testing might be harmful takes longer and often leaves patients dissatisfied. The entire medical-industrial complex—from drug companies to hospitals to medical device manufacturers—profits from intervention rather than restraint. This cultural bias toward action means medical care systematically errs on the side of overtreatment, subjecting patients to unnecessary interventions because doing nothing, even when appropriate, violates deeply embedded medical values.
21. What is the gray zone in pathology, and why can’t cellular appearance definitively predict cancer behavior?
The gray zone encompasses cellular abnormalities that fall between clearly benign and obviously malignant, representing about 20-25% of specimens. Here, pathologists must make subjective judgments about whether cells are atypical enough to constitute cancer. The same cells might be called inflammation by one pathologist, atypia by another, and cancer by a third. Cell appearance provides a static snapshot, but cancer behavior is dynamic, determined by complex interactions between tumor genetics, host immune response, and microenvironment that microscopy cannot assess.
Pathologists examine cellular architecture—how cells arrange themselves—and individual cell characteristics like nuclear size and shape. But cells that look threatening under the microscope may lack the genetic mutations necessary for invasion and metastasis, while innocent-appearing cells might harbor dangerous molecular changes. The microscope cannot reveal whether cancer cells will successfully evade immune surveillance, recruit blood vessels, survive in circulation, or establish metastatic colonies. This fundamental limitation means pathology, despite its scientific appearance, involves educated guessing about future biological behavior based on incomplete visual information.
22. How do quality metrics and electronic medical records distract doctors from patients’ actual concerns?
Electronic medical records generate lists of required preventive interventions—cancer screenings, vaccinations, health maintenance tasks—that dominate clinical encounters. Quality metrics judge physicians on completion rates for these predetermined tasks rather than addressing individual patient concerns. Doctors face computer screens showing overdue screenings in red, creating pressure to check boxes rather than listen to patients. A 15-minute appointment might require 10 minutes to address mandated screenings, leaving little time for the breathing problem or back pain that brought the patient in.
These systems transform medicine from responsive patient care to protocol-driven task completion. Physicians interrupt patient narratives to order mammograms or colonoscopies, prioritizing system-mandated prevention over immediate concerns. Quality scores and financial incentives reinforce this behavior, rewarding doctors for screening compliance rather than patient satisfaction or clinical judgment. The electronic medical record, designed to improve care, instead interposes itself between doctor and patient, creating encounters dominated by computer-generated agendas that may have little relevance to individual patient needs or preferences.
23. Why did kidney cancer survival rates improve dramatically without any real benefit to patients?
Kidney cancer five-year survival rose from 50% to 60% purely through earlier detection, not improved treatment. CT and MRI scans performed for other reasons incidentally detected small kidney cancers that previously would have remained hidden. These people survived five years not because treatment saved them but because their cancers were found years before symptoms would have appeared. The survival clock started earlier, creating longer survival times without changing when people actually died—pure lead time bias.
Additionally, many detected kidney cancers represented pseudodisease that never would have caused problems. Every person with harmless kidney cancer found incidentally became a five-year survivor, statistically improving outcomes while receiving no benefit from diagnosis and treatment. The death rate from kidney cancer remained completely stable throughout this period of “improving” survival, definitively proving that finding more kidney cancer didn’t save lives. Patients underwent nephrectomies with their 2% operative mortality and substantial complication rates for cancers that didn’t threaten them, demonstrating how survival statistics can show dramatic improvement while patients actually fare worse.
24. What does the Lawrence Livermore National Laboratory cancer cluster story teach us about cancer statistics?
When melanoma rates at Lawrence Livermore appeared elevated, investigations revealed not environmental contamination but dermatologists finding more melanomas through aggressive screening and low thresholds for biopsy. The “epidemic” resulted from diagnostic practice rather than disease occurrence. Dermatologists examined employees thoroughly, biopsied suspicious lesions liberally, and pathologists called borderline lesions cancer. This created statistically significant excess cancer without any increase in melanoma deaths, demonstrating how medical practice variations create false disease clusters.
The story illustrates how cancer statistics reflect diagnostic intensity more than true disease burden. Communities with more specialists, better insurance, or health-conscious populations show higher cancer rates not because they have more disease but because they look harder for it. These artificial elevations trigger anxiety, further medical investigations, and demands for environmental studies when the real “cause” is medical surveillance itself. Cancer statistics, rather than objective disease measures, become artifacts of healthcare access, physician practice patterns, and cultural attitudes toward screening.
25. How should individuals approach the personal decision about whether to be screened for cancer?
Individual screening decisions should reflect personal values about uncertainty, risk tolerance, and what constitutes a life well-lived. People terrified of cancer who would regret not doing “everything possible” might reasonably choose aggressive screening despite false positives and overdiagnosis risks. Others who prioritize avoiding medical interventions and accept uncertainty might reasonably decline screening. The decision depends on how individuals weigh small chances of benefit against larger chances of harm, and how they value length of life versus quality of life.
Context matters enormously: age, health status, family history, and life circumstances all influence the calculation. A healthy 50-year-old might reasonably screen differently than a frail 80-year-old with heart disease. The key is making informed rather than automatic decisions, understanding that screening isn’t simply “prevention” but rather a complex intervention with both benefits and harms. People should resist one-size-fits-all recommendations and marketing that presents screening as obviously beneficial, instead thoughtfully considering whether looking for cancer aligns with their personal goals and values.
26. What is the multi-step nature of cancer development, and why doesn’t one abnormality necessarily lead to death?
Cancer develops through multiple sequential steps, each requiring specific failures: DNA mutations must occur and evade repair mechanisms, abnormal cells must escape destruction by suicide programs or immune surveillance, growing tumors must recruit blood supplies, and cancer cells must acquire abilities to invade, survive in circulation, and establish distant colonies. Each step represents an opportunity for the process to halt. Most DNA mutations get repaired, most abnormal cells get destroyed, and most early cancers fail to progress. The body maintains multiple defense mechanisms that usually succeed.
This multi-step process explains why finding cellular abnormalities doesn’t predict death. A collection of atypical cells might lack crucial mutations for invasion, or the host immune system might successfully contain them. Some cancers outgrow their blood supply and starve, others remain dormant for decades, and some spontaneously regress. The cascade from mutation to metastasis to death isn’t inevitable but rather highly contingent, with failure more common than success. Our detection methods identify abnormalities at various steps in this process but cannot determine which will successfully navigate all barriers to become lethal disease.
27. How does the promotion of cancer awareness inadvertently make healthy people feel sick?
Cancer awareness campaigns encourage constant vigilance about bodies, promoting anxiety about hidden diseases. People are told to perform regular self-examinations, watch for warning signs, and undergo frequent screening. This transforms normal bodily variation into potential threats requiring medical evaluation. The worried well flood doctors’ offices seeking reassurance about symptoms they previously would have ignored. Health becomes the absence of detectable abnormalities rather than the presence of wellbeing.
The medicalization of risk means millions live as “pre-patients”—women with dense breasts requiring extra screening, men with elevated PSA needing surveillance, people with genetic variants warranting increased monitoring. These labels create persistent anxiety about cancers that might never occur. Cancer awareness, rather than empowering people, creates a culture of fear where healthy people constantly worry about hidden malignancies. The psychological burden of perpetual cancer anxiety might exceed any benefit from early detection, transforming a population of healthy individuals into worried potential patients.
28. What are interval cancers and what do they reveal about the limitations of screening programs?
Interval cancers appear between scheduled screenings, becoming symptomatic before the next test. These tend to be aggressive, fast-growing cancers that progress from undetectable to symptomatic within the screening interval. Women who develop interval breast cancers between annual mammograms often have more aggressive tumors than those whose cancers are screen-detected, and their prognosis is correspondingly worse despite participating in screening programs.
Interval cancers expose screening’s fundamental limitation: the cancers most needing early detection are least likely to be caught by periodic testing. Aggressive cancers sprint through the detection window while indolent cancers linger for years, creating length bias where screening preferentially catches good-prognosis cancers while missing dangerous ones. The existence of interval cancers means even perfect screening compliance cannot prevent cancer deaths from aggressive tumors. These cases demonstrate that screening cannot overcome cancer biology—the deadliest cancers evade detection while harmless ones fill screening programs.
29. Why is overall mortality rather than cancer-specific mortality the most important measure of screening effectiveness?
Overall mortality captures all consequences of screening—both benefits and harms—while cancer-specific mortality can be manipulated through attribution bias and misses deaths from treatment. Screening might reduce cancer deaths while increasing deaths from surgical complications, radiation-induced secondary cancers, or cardiovascular effects of treatment. Only overall mortality reveals whether people actually live longer. Additionally, determining cause of death involves subjective judgments that can favor screening programs.
Studies showing cancer mortality reductions without overall mortality benefits suggest screening redistributes rather than prevents deaths. The focus on disease-specific mortality allows screening advocates to claim success while ignoring broader harms. If screening truly provided substantial benefit, overall mortality would improve detectably. The failure to demonstrate overall mortality benefits in most screening trials, despite massive sample sizes, indicates that screening’s net effect on lifespan is marginal at best and possibly negative when all consequences are considered.
30. What fundamental questions should patients ask their doctors before agreeing to cancer screening?
Patients should ask about absolute risk reduction: “Of 1,000 people like me who get screened, how many will live longer?” not just relative risk percentages. They should understand false positive rates: “How likely am I to have a cancer scare that turns out to be nothing?” and the cumulative risk over multiple screenings. Questions about overdiagnosis are crucial: “How many cancers found by screening would never have caused problems?” Understanding downstream consequences matters: “If the test is positive, what additional procedures might I need?”
Most importantly, patients should ask whether doctors would make the same choice for themselves or their families, and why. Questions about alternatives—watchful waiting, less frequent screening, or different tests—reveal options beyond all-or-nothing approaches. Patients should inquire about the strength of evidence supporting screening in their specific situation rather than accepting population-based recommendations. These questions transform screening from automatic compliance to informed decision-making, acknowledging that the right choice varies among individuals based on personal values and circumstances.
I appreciate you being here.
If you’ve found the content interesting, useful and maybe even helpful, please consider supporting it through a small paid subscription. While 99% of everything here is free, your paid subscription is important as it helps in covering some of the operational costs and supports the continuation of this independent research and journalism work. It also helps keep it free for those that cannot afford to pay.
Please make full use of the Free Libraries.
Unbekoming Interview Library: Great interviews across a spectrum of important topics.
Unbekoming Book Summary Library: Concise summaries of important books.
Stories
I’m always in search of good stories, people with valuable expertise and helpful books. Please don’t hesitate to get in touch at unbekoming@outlook.com
Baseline Human Health
Watch and share this profound 21-minute video to understand and appreciate what health looks like without vaccination.
I don't do any type of testing for health concerns.
Experience...especially of the last 10 to 12 years, says never give the medics any excuse to examine your most private self. They are not doing it for your benefit, very often...